New pill targets Hard-to-Treat cancers with missing gene
NCT ID NCT05732831
First seen Nov 16, 2025 · Last updated May 01, 2026 · Updated 18 times
Summary
This study is testing a new drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to shrink or control tumor growth. The trial has two parts: first finding the best dose, then testing it in more patients with certain tumor types. Up to 225 adults with good organ function and no other treatment options may join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Brest
RECRUITINGBrest, 29200, France
Contact
-
Carle Cancer Center
RECRUITINGUrbana, Illinois, 61801, United States
Contact
-
Centre Berard Leon
RECRUITINGLyon, 69373, France
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Florida Cancer Specialists & Research Institute
COMPLETEDLake Mary, Florida, 32746, United States
-
Grand Valley Oncology
RECRUITINGGrand Junction, Colorado, 81505, United States
Contact
-
Henry Ford Cancer Center
RECRUITINGDetroit, Michigan, 48202, United States
Contact
-
Hospital HM Nou Delfos
RECRUITINGBarcelona, 08023, Spain
Contact
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
Contact
-
Hospital Universitario Virgen de la Victoria
RECRUITINGMálaga, 29010, Spain
Contact
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, 41013, Spain
Contact
-
Hospital de Sanchinarro
RECRUITINGMadrid, 28050, Spain
Contact
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact
-
ICO l'Hospitalet - Hospital Duran i Reynals
RECRUITINGBarcelona, 08908, Spain
Contact
-
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS
RECRUITINGSaint-Herblain, 44805, France
Contact
-
Institute Gustav Roussy
RECRUITINGVillejuif, 94805, France
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02214, United States
Contact
-
Midwestern Regional Medical Center, City of Hope Chicago
RECRUITINGZion, Illinois, 60099, United States
Contact
-
New York University Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
-
Next Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Sarah Cannon Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
-
Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University Chicago Medicine
RECRUITINGChicago, Illinois, 60637, United States
Contact
-
Vall d'Hebron Barcelona Hospital
RECRUITINGBarcelona, Catalonia, Spain
Contact
Conditions
Explore the condition pages connected to this study.